Phytocannabinoids, CNS cells and development: A dead issue?

Drug and Alcohol Review

Volumn 29, Issue 1, 2010, Pages 91-98

  Downer, Eric J ^a   Campbell, Veronica A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cell fate; CNS cell; Development; Marijuana; Phytocannabinoid

Indexed keywords

CANNABINOID; CANNABIS;

ADOLESCENT; ADULT; AGE; ANIMAL; CANNABIS SMOKING; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; NERVE CELL; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CANNABINOIDS; CANNABIS; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; INFANT, NEWBORN; MARIJUANA SMOKING; NEURONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 77149177641     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2009.00102.x     Document Type: Review

References (100)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
3. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006;27:1-4.
4. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007;152:825-31.
5. Hajos N, Ledent C, Freund TF. Novel cannabinoidsensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001;106:1-4.
6. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 1999;96:14136-41.
7. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
8. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
9. Yamauchi T, Shoyama Y, Matsuo Y, Nishioka I. Cannabigerol monomethyl ether, a new component of hemp. Chem Pharm Bull (Tokyo) 1968;16:1164-5.
10. Crombie L, Ponsford R, Shani A, Yagnitinsky B, Mechoulam R. Hashish components. Photochemical production of cannabicyclol from cannabichromene. Tetrahedron Lett 1968;55:5771-2.
11. ElSohly MA, Feng S, Murphy TP, et al. Delta 9-tetrahydrocannabivarin (delta 9-THCV) as a marker for the ingestion of cannabis versus Marinol. J Anal Toxicol 1999;23:222-4.
12. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002;95:175-84.
13. Carlini EA. The good and the bad effects of (-) transdelta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 2004;44:461-7.
14. Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001;69:343-50.
15. Sethi BB, et al. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol Psychiatry 1986;21:3-10.
16. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
17. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306.
18. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007;8:373-84.
19. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alphaconverting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64:1943-50.
20. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-19.
21. Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 1998;18:5322-32.
22. Kim D, Thayer SA. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 2001;21:RC146.
23. Campbell VA. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology 2001;40:702-9.
24. Downer E, Boland B, Fogarty M, Campbell V. Delta 9-tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport 2001;12:3973-8.
25. McAllister SD, Chan C, Taft RJ, et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 2005;74:31-40.
26. Carracedo A, Lorente M, Egia A, et al. The stressregulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006;9:301-12.
27. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998;95:8268-73.
28. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a nonpsychoactive component from Cannabis sativa, on betaamyloid-induced toxicity in PC12 cells. J Neurochem 2004;89:134-41.
29. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007;1128:61-9.
30. Abood ME, Rizvi G, Sallapudi N, McAllister SD. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001;309:197-201.
31. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005;19:96-107.
32. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-9.
33. Hayakawa K, Mishima K, Nozako M, et al. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidaseinhibiting mechanism. J Neurochem 2007;102:1488-96.
34. Downer EJ, Gowran A, Campbell VA. A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res 2007; 1175:39-47.
35. Suarez I, Bodega G, Ramos JA, Fernandez-Ruiz JJ, Fernandez B. Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra-hydrocannabinol in the rat substantia nigra. Dev Neurosci 2000;22:253-63.
36. Rivkin MJ, Davis PE, Lemaster JL, et al. Volumetric MRI study of brain in children with intrauterine exposure to cocaine, alcohol, tobacco, and marijuana. Pediatrics 2008;121:741-50.
37. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000;19:1-22.
38. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 1977;237:1229-30.
39. Hannerz J, Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Ann Neurol 1983;13:207-10.
40. Tzilos GK, Cintron CB, Wood JB, et al. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict 2005;14:64-72.
41. Delisi LE, Bertisch HC, Szulc K, et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduct J 2006;3:17.
42. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000;11:491-6.
43. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005;77:23-30.
44. Schlaepfer TE, Lancaster E, Heidbreder R, et al. Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol 2006;9:147-53.
45. Yucel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008;65:694-701.
46. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008;41:1067-74.
47. Scallet AC, Uemura E, Andrews A, et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 1987;436:193-8.
48. Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 1991;40:671-6.
49. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.
50. Fernandez-Ruiz JJ, Berrendero F, Hernandez ML, Romero J, Ramos JA. Role of endocannabinoids in brain development. Life Sci 1999;65:725-36.
51. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999;33:181-91.
52. Berrendero F, Garcia-Gil L, Hernandez ML, et al. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 1998;125:3179-88.
53. Romero J, Garcia-Palomero E, Berrendero F, et al. Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 1997;26:317-23.
54. Harkany T, Keimpema E, Barabas K, Mulder J. Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol 2008; 286(1-2 Suppl 1):S84-90.
55. Arevalo-Martin A, Garcia-Ovejero D, Rubio-Araiz A, Gomez O, Molina-Holgado F, Molina-Holgado E. Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2. Eur J Neurosci 2007;26:1548-59.
56. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007;13:109-14.
57. Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007;316:1212-16.
58. Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 1989;44:697-701.
59. Downer EJ, Fogarty MP, Campbell VA. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 2003; 140:547-57.
60. Downer EJ, Gowran A, Murphy AC, Campbell VA. The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurons. Eur J Pharmacol 2007;564:57-65.
61. Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 1997;60:1563-73.
62. Abel EL. Effects of delta 9-THC on pregnancy and offspring in rats. Neurobehav Toxicol Teratol 1984;6:29-32.
63. Suarez I, Bodega G, Rubio M, Fernandez-Ruiz JJ, Ramos JA, Fernandez B. Prenatal cannabinoid exposure downregulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum. Dev Neurosci 2004;26:45-53.
64. Newsom RJ, Kelly SJ. Perinatal delta-9-tetrahydrocannabinol exposure disrupts social and open field behavior in adult male rats. Neurotoxicol Teratol 2008;30:213-19.
65. NavarroM, de Miguel R, Rodriguez de Fonseca F, Ramos JA, Fernandez-Ruiz JJ. Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behav Brain Res 1996;75:91-8.
66. Martin BR, Dewey WL, Harris LS, Beckner JS. 3H-delta9-tetrahydrocannabinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 1977;17:457-70.
67. Jakubovic A, Hattori T, McGeer PL. Radioactivity in suckled rats after giving 14 C-tetrahydrocannabinol to the mother. Eur J Pharmacol 1973;22:221-3.
68. Fernandez-Ruiz J, De Miguel R, Hernandez ML, Cebeira M, Ramos JA. Comparisons between brain dopaminergic neurons of juvenile and aged rats: sex-related differences. Mech Ageing Dev 1992;63:45-55.
69. Dalterio SL. Cannabinoid exposure: effects on development. Neurobehav Toxicol Teratol 1986;8:345-52.
70. Molina-Holgado F, Amaro A, Gonzalez MI, Alvarez FJ, Leret ML. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system. Eur J Pharmacol 1996;316:39-42.
71. Kumar AM, Haney M, Becker T, Thompson ML, Kream RM, Miczek K. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Res 1990;525:78-83.
72. Suarez I, Bodega G, Fernandez-Ruiz JJ, Ramos JA, Rubio M, Fernandez B. Reduced glial fibrillary acidic protein and glutamine synthetase expression in astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-tetrahydrocannabinol administration during development. Dev Neurosci 2002;24:300-12.
73. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int 2002;128:20-30.
74. Fried PA. The Ottawa Prenatal Prospective Study (OPPS): methodological issues and findings-it's easy to throw the baby out with the bath water. Life Sci 1995; 56:2159-68.
75. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol 1990;12:161-8.
76. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001;23:1-11.
77. Fried PA, Watkinson B. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr 1990;11:49-58.
78. Griffith DR, Azuma SD, Chasnoff IJ. Three-year outcome of children exposed prenatally to drugs. J Am Acad Child Adolesc Psychiatry 1994;33:20-7.
79. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and academic achievement at age 10. NeurotoxicolTeratol 2004;26:521-32.
80. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 2005;27:439-48.
81. Schneider M, Koch M. The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 2007;17:180-6.
82. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 2008;13:253-63.
83. Dalterio SL, Bernard SA, Esquivel CR. Acute delta 9-tetrahydrocannabinol exposure alters Ca2+ ATPase activity in neuroendocrine and gonadal tissues in mice. Eur J Pharmacol 1987;137:91-100.
84. Stiglick A, Kalant H. Residual effects of chronic cannabis treatment on behavior in mature rats. Psychopharmacology (Berl) 1985;85:436-9.
85. Cha YM, White AM, Kuhn CM, Wilson WA, Swartzwelder HS. Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav 2006;83:448-55.
86. Ehrenreich H, Rinn T, Kunert HJ, et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 1999;142:295-301.
87. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003;28:1760-9.
88. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-27.
89. Kalkman HO. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol Ther 2009;121:115-22.
90. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006;81:47-63.
91. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110-17.
92. Solowij N, Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 2007;32:30-52.
93. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-94.
94. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001;103:9-15.
95. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10:1665-9.
96. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992;13:201-6.
97. Block RI, Ghoneim MM. Effects of chronic marijuana use on human cognition. Psychopharmacology (Berl) 1993; 110:219-28.
98. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101-6.
99. Buchan BJ, Walsh JM, Leaverton PE. Evaluation of the accuracy of on-site multi-analyte drug testing devices in the determination of the prevalence of illicit drugs in drivers. J Forensic Sci 1998;43:395-9.
100. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996;30:109-17.